Franklin Resources Inc. Purchases New Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Franklin Resources Inc. acquired a new stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 433,482 shares of the company's stock, valued at approximately $2,189,000. Franklin Resources Inc. owned approximately 0.34% of Humacyte at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in HUMA. State Street Corp boosted its position in shares of Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company's stock valued at $25,917,000 after purchasing an additional 1,895,529 shares during the period. Vanguard Group Inc. lifted its stake in Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock valued at $28,294,000 after buying an additional 543,995 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of Humacyte by 217.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 415,262 shares of the company's stock worth $2,097,000 after buying an additional 284,368 shares during the period. Private Advisor Group LLC increased its position in shares of Humacyte by 60.7% in the fourth quarter. Private Advisor Group LLC now owns 599,700 shares of the company's stock worth $3,028,000 after acquiring an additional 226,590 shares in the last quarter. Finally, LJI Wealth Management LLC acquired a new stake in shares of Humacyte during the fourth quarter valued at approximately $934,000. Institutional investors and hedge funds own 44.71% of the company's stock.

Insider Activity at Humacyte

In related news, Director Kathleen Sebelius purchased 50,000 shares of Humacyte stock in a transaction on Tuesday, April 8th. The stock was bought at an average price of $1.32 per share, with a total value of $66,000.00. Following the completion of the transaction, the director now directly owns 91,207 shares of the company's stock, valued at approximately $120,393.24. This represents a 121.34 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Dale A. Sander acquired 20,000 shares of the stock in a transaction dated Thursday, April 10th. The shares were bought at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the acquisition, the chief financial officer now owns 40,600 shares in the company, valued at $62,118. The trade was a 97.09 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 83,993 shares of company stock valued at $118,224. Insiders own 11.20% of the company's stock.

Humacyte Price Performance

HUMA traded up $0.13 during trading on Friday, reaching $1.68. 3,081,887 shares of the stock traded hands, compared to its average volume of 3,568,026. The stock's 50-day simple moving average is $2.61 and its two-hundred day simple moving average is $4.05. Humacyte, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $9.97. The stock has a market cap of $260.60 million, a price-to-earnings ratio of -1.25 and a beta of 1.62.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.07. The firm had revenue of $7.23 million during the quarter, compared to the consensus estimate of $0.64 million. Research analysts anticipate that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on HUMA. Benchmark reaffirmed a "buy" rating on shares of Humacyte in a research note on Thursday, February 27th. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 target price on shares of Humacyte in a research report on Wednesday, March 26th. Finally, HC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of Humacyte in a research report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.